Compare TKLF & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | CLGN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 18.4M |
| IPO Year | 2022 | N/A |
| Metric | TKLF | CLGN |
|---|---|---|
| Price | $2.94 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 7.8K | ★ 114.3K |
| Earning Date | 12-19-2025 | 03-25-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $302,537,158.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | $85.83 |
| P/E Ratio | $2.88 | ★ N/A |
| Revenue Growth | 37.82 | ★ 280.77 |
| 52 Week Low | $2.10 | $0.59 |
| 52 Week High | $4.32 | $4.98 |
| Indicator | TKLF | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 26.39 |
| Support Level | $2.28 | $0.66 |
| Resistance Level | $3.19 | $1.99 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 54.39 | 6.52 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.